Equities Analysts Issue Forecasts for EWTX FY2026 Earnings

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) - Wedbush dropped their FY2026 earnings per share (EPS) estimates for Edgewise Therapeutics in a note issued to investors on Monday, March 3rd. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($2.25) per share for the year, down from their prior forecast of ($2.24). The consensus estimate for Edgewise Therapeutics' current full-year earnings is ($1.45) per share. Wedbush also issued estimates for Edgewise Therapeutics' FY2029 earnings at $3.99 EPS.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last announced its earnings results on Monday, March 3rd. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.03).

Several other research firms also recently weighed in on EWTX. Truist Financial lifted their price target on shares of Edgewise Therapeutics from $33.00 to $50.00 and gave the company a "buy" rating in a research note on Wednesday, November 27th. Evercore ISI raised their price objective on Edgewise Therapeutics from $45.00 to $50.00 and gave the company an "outperform" rating in a research note on Tuesday, December 17th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $56.00 target price on shares of Edgewise Therapeutics in a research report on Tuesday, March 4th. Stifel Nicolaus started coverage on shares of Edgewise Therapeutics in a research report on Wednesday, January 22nd. They issued a "hold" rating and a $30.00 price target for the company. Finally, Scotiabank started coverage on shares of Edgewise Therapeutics in a research note on Friday. They issued a "sector outperform" rating and a $50.00 price objective on the stock. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Edgewise Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $45.38.

Remove Ads

Edgewise Therapeutics Trading Down 1.7 %

EWTX stock traded down $0.48 during midday trading on Thursday, hitting $27.53. The stock had a trading volume of 1,263,374 shares, compared to its average volume of 919,123. The business has a fifty day moving average price of $26.77 and a two-hundred day moving average price of $27.93. Edgewise Therapeutics has a 1-year low of $14.90 and a 1-year high of $38.12. The firm has a market cap of $2.62 billion, a P/E ratio of -18.35 and a beta of 0.22.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Edgewise Therapeutics in the fourth quarter valued at approximately $2,404,000. GF Fund Management CO. LTD. purchased a new position in Edgewise Therapeutics in the 4th quarter worth approximately $53,000. Neo Ivy Capital Management bought a new position in Edgewise Therapeutics in the fourth quarter valued at $259,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Edgewise Therapeutics by 231.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 279,125 shares of the company's stock valued at $7,453,000 after buying an additional 194,831 shares in the last quarter. Finally, Woodline Partners LP raised its stake in shares of Edgewise Therapeutics by 7.5% during the fourth quarter. Woodline Partners LP now owns 567,218 shares of the company's stock worth $15,145,000 after acquiring an additional 39,379 shares in the last quarter.

Insiders Place Their Bets

In related news, insider Marc Semigran sold 29,709 shares of the business's stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $29.69, for a total value of $882,060.21. Following the transaction, the insider now directly owns 6,716 shares of the company's stock, valued at approximately $199,398.04. The trade was a 81.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Alan J. Russell sold 1,200 shares of the firm's stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $30.13, for a total transaction of $36,156.00. Following the sale, the insider now owns 14,863 shares of the company's stock, valued at $447,822.19. This trade represents a 7.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 164,545 shares of company stock valued at $4,605,305 in the last 90 days. 24.11% of the stock is currently owned by corporate insiders.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.